Iris Allajbeu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Iris Allajbeu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Fiona J. Gilbert
University of Cambridge
2 shared publications - Allison Rose
The Royal Melbourne Hospital, Grattan Street Parkville 3052 Victoria, Australia; The Royal Women's Hospital, Flemington Road, Parkville 3052 Victoria Australia; The University of Melbourne Parkville 3052 Victoria Australia
1 shared publication Almir G.V. Bitencourt
Imaging Department, A.C.Camargo Cancer Center, São Paulo, Brazil; DASA, São Paulo, Brazil
1 shared publication- Anat Kornecki
St. Joseph’s Health Care London, Western University, ON, Canada
1 shared publication - Andrew Nicholas Priest
Department of Radiology, University of Cambridge, Cambridge, UK
1 shared publication - Bhavika K. Patel
Department of Radiology, Mayo Clinic, Phoenix, AZ, USA
1 shared publication
Latest Publications
- Open Access
- 16 January 2026
- Published by Springer Nature in Insights into Imaging
- Vol. 17 (1) , 14
Acceptance, experience, and feedback for supplemental screening in dense breasts among women participating in the BRAID trial
Objectives: To evaluate patient acceptance and feedback regarding supplemental imaging modalities: automated whole-breast ultrasound (ABUS), contrast-enhanced mammography (CEM), and abbreviated breast MRI (AB-MRI) within the BRAID (Breast Screening: Risk Adaptive Imaging for Density) trial. Materials and methods: An adapted Testing Morbidities Index questionnaire was utilised to capture participant experiences and perceptions (January-April 2024) related to AB-MRI, ABUS and CEM. Likert-scale questions assessed discomfort, anxiety, and overall satisfaction for each imaging modality, while thematic analysis was applied to free-text patient feedback. Additionally, reasons for withdrawal were recorded for each modality. Results: Among 159 women providing feedback, 57/159 (35.8%) underwent ABUS, 52/159 (32.7%) CEM, and 50/159 (31.5%) AB-MRI. Acceptability of ABUS, CEM and AB-MRI was rated similarly to mammography by 71/159 (64.8%) of these respondents, with 72/159 (45.3%) considering them superior. Mild-to-moderate discomfort due to breast compression was reported for ABUS and CEM, whereas AB-MRI resulted in the least discomfort. Pre-procedural anxiety was observed across all imaging modalities, particularly with contrast-enhanced techniques; however, experiences were generally well-tolerated. Effective communication and pre-test information reduced anxiety levels, with most participants willing to repeat the procedures. 151/984 (15.3%) withdrawals in BRAID were due to adverse patient experiences, with contrast-enhanced techniques accounting for most of these withdrawals (CEM: 69/151, 45.7%; AB-MRI: 66/151, 43.7%; ABUS: 12/151, 7.9%). The main reasons for withdrawal were unhappiness with the allocated imaging arm and discomfort or anxiety during the procedure. Conclusion: Supplemental imaging modalities are generally well-accepted by patients with benefit throughout gained by clear communication and preparedness. Critical relevance statement: Feedback from a subgroup of women participating in the BRAID trial shows that supplemental imaging alongside routine screening is well-accepted. Clear communication and empathetic care further improve acceptance, supporting a shift toward personalised breast cancer screening for women with dense breasts. Key Points: Understanding women’s imaging experiences is essential for optimising breast screening practices. Acceptability of supplemental imaging was rated similar to or better than mammography by most participants. Clear, empathetic communication reduced anxiety and improved experience with contrast-enhanced imaging. Graphical
- 16 January 2026
- Published by Springer Nature in Insights into Imaging
- Vol. 17 (1) , 14
Open AccessAcceptance, experience, and feedback for supplemental screening in dense breasts among women participating in the BRAID trial
Objectives: To evaluate patient acceptance and feedback regarding supplemental imaging modalities: automated whole-breast ultrasound (ABUS), contrast-enhanced mammography (CEM), and abbreviated breast MRI (AB-MRI) within the BRAID (Breast Screening: Risk Adaptive Imaging for Density) trial. Materials and methods: An adapted Testing Morbidities Index questionnaire was utilised to capture participant experiences and perceptions (January-April 2024) related to AB-MRI, ABUS and CEM. Likert-scale questions assessed discomfort, anxiety, and overall satisfaction for each imaging modality, while thematic analysis was applied to free-text patient feedback. Additionally, reasons for withdrawal were recorded for each modality. Results: Among 159 women providing feedback, 57/159 (35.8%) underwent ABUS, 52/159 (32.7%) CEM, and 50/159 (31.5%) AB-MRI. Acceptability of ABUS, CEM and AB-MRI was rated similarly to mammography by 71/159 (64.8%) of these respondents, with 72/159 (45.3%) considering them superior. Mild-to-moderate discomfort due to breast compression was reported for ABUS and CEM, whereas AB-MRI resulted in the least discomfort. Pre-procedural anxiety was observed across all imaging modalities, particularly with contrast-enhanced techniques; however, experiences were generally well-tolerated. Effective communication and pre-test information reduced anxiety levels, with most participants willing to repeat the procedures. 151/984 (15.3%) withdrawals in BRAID were due to adverse patient experiences, with contrast-enhanced techniques accounting for most of these withdrawals (CEM: 69/151, 45.7%; AB-MRI: 66/151, 43.7%; ABUS: 12/151, 7.9%). The main reasons for withdrawal were unhappiness with the allocated imaging arm and discomfort or anxiety during the procedure. Conclusion: Supplemental imaging modalities are generally well-accepted by patients with benefit throughout gained by clear communication and preparedness. Critical relevance statement: Feedback from a subgroup of women participating in the BRAID trial shows that supplemental imaging alongside routine screening is well-accepted. Clear communication and empathetic care further improve acceptance, supporting a shift toward personalised breast cancer screening for women with dense breasts. Key Points: Understanding women’s imaging experiences is essential for optimising breast screening practices. Acceptability of supplemental imaging was rated similar to or better than mammography by most participants. Clear, empathetic communication reduced anxiety and improved experience with contrast-enhanced imaging. Graphical
- Open Access
- 16 July 2025
- Published by Elsevier in European Journal of Radiology
- Vol. 191, 112315
Overview of different reimbursement strategies among contrast-enhanced mammography (CEM) expert centers on a global level – A survey study
- 16 July 2025
- Published by Elsevier in European Journal of Radiology
- Vol. 191, 112315
Open AccessOverview of different reimbursement strategies among contrast-enhanced mammography (CEM) expert centers on a global level – A survey study
- 1 August 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (2) , e232303
Accuracy of an Artificial Intelligence System for Interval Breast Cancer Detection at Screening Mammography
An artificial intelligence algorithm accurately detected one-quarter of interval cancers on screening mammograms and accurately located three-quarters of them, which could result in earlier detection of breast cancer.
- 1 August 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (2) , e232303
Accuracy of an Artificial Intelligence System for Interval Breast Cancer Detection at Screening Mammography
An artificial intelligence algorithm accurately detected one-quarter of interval cancers on screening mammograms and accurately located three-quarters of them, which could result in earlier detection of breast cancer.
- Open Access
- 23 June 2021
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 13 (3) , 141-150
Automated Breast Ultrasound: Technical Aspects, Impact on Breast Screening, and Future Perspectives
Purpose of Review: Automated breast ultrasound (ABUS) is a three-dimensional imaging technique, used as a supplemental screening tool in women with dense breasts. This review considers the technical aspects, pitfalls, and the use of ABUS in screening and clinical practice, together with new developments and future perspectives. Recent Findings: ABUS has been approved in the USA and Europe as a screening tool for asymptomatic women with dense breasts in addition to mammography. Supplemental US screening has high sensitivity for cancer detection, especially early-stage invasive cancers, and reduces the frequency of interval cancers. ABUS has similar diagnostic performance to handheld ultrasound (HHUS) and is designed to overcome the drawbacks of operator dependence and poor reproducibility. Concerns with ABUS, like HHUS, include relatively high recall rates and lengthy reading time when compared to mammography. ABUS is a new technique with unique features; therefore, adequate training is required to improve detection and reduce false positives. Computer-aided detection may reduce reading times and improve cancer detection. Other potential applications of ABUS include local staging, treatment response evaluation, breast density assessment, and integration of radiomics. Summary: ABUS provides an efficient, reproducible, and comprehensive supplemental imaging technique in breast screening. Developments with computer-aided detection may improve the sensitivity and specificity as well as radiologist confidence and reduce reading times, making this modality acceptable in large volume screening centers.
- 23 June 2021
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 13 (3) , 141-150
Open AccessAutomated Breast Ultrasound: Technical Aspects, Impact on Breast Screening, and Future Perspectives
Purpose of Review: Automated breast ultrasound (ABUS) is a three-dimensional imaging technique, used as a supplemental screening tool in women with dense breasts. This review considers the technical aspects, pitfalls, and the use of ABUS in screening and clinical practice, together with new developments and future perspectives. Recent Findings: ABUS has been approved in the USA and Europe as a screening tool for asymptomatic women with dense breasts in addition to mammography. Supplemental US screening has high sensitivity for cancer detection, especially early-stage invasive cancers, and reduces the frequency of interval cancers. ABUS has similar diagnostic performance to handheld ultrasound (HHUS) and is designed to overcome the drawbacks of operator dependence and poor reproducibility. Concerns with ABUS, like HHUS, include relatively high recall rates and lengthy reading time when compared to mammography. ABUS is a new technique with unique features; therefore, adequate training is required to improve detection and reduce false positives. Computer-aided detection may reduce reading times and improve cancer detection. Other potential applications of ABUS include local staging, treatment response evaluation, breast density assessment, and integration of radiomics. Summary: ABUS provides an efficient, reproducible, and comprehensive supplemental imaging technique in breast screening. Developments with computer-aided detection may improve the sensitivity and specificity as well as radiologist confidence and reduce reading times, making this modality acceptable in large volume screening centers.